Home » Stocks » Jazz Pharmaceuticals

Jazz Pharmaceuticals PLC (JAZZ)

Stock Price: $148.75 USD 3.36 (2.31%)
Updated Oct 22, 2020 10:12 AM EDT - Market open

Stock Price Chart

Key Info

Market Cap 8.25B
Revenue (ttm) 2.22B
Net Income (ttm) 133.24M
Shares Out 55.46M
EPS (ttm) 2.36
PE Ratio 63.03
Forward PE 9.50
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 22, 2020
Last Price $148.75
Previous Close $145.39
Change ($) 3.36
Change (%) 2.31%
Day's Open 148.26
Day's Range 146.03 - 149.60
Day's Volume 85,019
52-Week Range 86.88 - 156.27

More Stats

Market Cap 8.25B
Enterprise Value 8.80B
Earnings Date (est) Nov 2, 2020
Ex-Dividend Date n/a
Shares Outstanding 55.46M
Float 53.40M
EPS (basic) 2.37
EPS (diluted) 2.36
FCF / Share 15.69
Dividend n/a
Dividend Yield n/a
Earnings Yield 1.59%
FCF Yield 10.54%
Payout Ratio n/a
Shares Short 4.76M
Short Ratio 4.18
Short % of Float 8.91%
Beta 1.15
PE Ratio 63.03
Forward PE 9.50
P/FCF Ratio 9.49
PS Ratio 3.72
PB Ratio 2.65
Revenue 2.22B
Operating Income 202.80M
Net Income 133.24M
Free Cash Flow 869.25M
Net Cash -551.24M
Net Cash / Share -9.94
Gross Margin 91.75%
Operating Margin 9.15%
Profit Margin 6.00%
FCF Margin 39.22%
ROA 7.04%
ROE 4.35%
ROIC 6.40%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (20)

Buy 16
Overweight 1
Hold 2
Underweight 0
Sell 1

Analyst Consensus: Buy

Price Target

$171.61*
(15.37% upside)
Low
117
Current: $148.75
High
205
Target: 171.61
*Average 12-month price target from 18 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue2,1621,8911,6191,4881,3251,173872586272174
Revenue Growth14.32%16.82%8.79%12.32%12.95%34.44%48.88%115.21%56.68%-
Gross Profit2,0341,7691,5091,3831,2221,055770508258160
Operating Income53261552959250819634019812857.79
Net Income52344748839733058.3921628912532.78
Shares Outstanding56.7559.9860.0260.5061.2359.7558.3056.6441.5036.34
Earnings Per Share9.097.307.966.415.230.933.514.792.670.83
EPS Growth24.52%-8.29%24.18%22.56%462.37%-73.5%-26.72%79.4%221.69%-
Operating Cash Flow77679969359253240828825015258.87
Capital Expenditures-40.14-20.37-28.95-9.69-35.96-36.35-9.98-5.98-1.28-0.73
Free Cash Flow73677966458349637127824415058.14
Cash & Equivalents1,07782560142698968463738715845.19
Total Debt1,7581,5961,5812,0301,1881,342550457-48.04
Net Cash / Debt-681-772-980-1,604-200-65886.53-69.57158-2.85
Assets5,5395,2035,1244,8003,3333,3392,2381,966254136
Liabilities2,4282,4462,4112,9231,7341,96894384560.79105
Book Value3,1112,7572,7131,8771,5991,3711,2961,12119330.55
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Jazz Pharmaceuticals PLC
Country Ireland
Employees 1,620
CEO Bruce C. Cozadd

Stock Information

Ticker Symbol JAZZ
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: JAZZ
IPO Date June 1, 2007

Description

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in adult and pediatric patients with narcolepsy; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; and Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia. The company also offers JZP-258, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for some narcolepsy patients; JZP-385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP-458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and lurbinectedin, a product candidate under clinical investigation for the treatment of patients with relapsed small cell lung cancer. Jazz Pharmaceuticals plc has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc . The company was founded in 2003 and is headquartered in Dublin, Ireland.